Effectiveness of the delivery of interventions to prevent malaria in pregnancy in Kenya. by Dellicour, Stephanie et al.
Dellicour, S; Hill, J; Bruce, J; Ouma, P; Marwanga, D; Otieno, P; De-
sai, M; Hamel, MJ; Kariuki, S; Webster, J (2016) Effectiveness of the
delivery of interventions to prevent malaria in pregnancy in Kenya.
Malar J, 15 (1). p. 221. ISSN 1475-2875 DOI: 10.1186/s12936-016-
1261-2
Downloaded from: http://researchonline.lshtm.ac.uk/2545987/
DOI: 10.1186/s12936-016-1261-2
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Dellicour et al. Malar J  (2016) 15:221 
DOI 10.1186/s12936-016-1261-2
RESEARCH
Effectiveness of the delivery 
of interventions to prevent malaria 
in pregnancy in Kenya
Stephanie Dellicour1*, Jenny Hill1, Jane Bruce2, Peter Ouma3, Doris Marwanga3, Peter Otieno3, Meghna Desai4, 
Mary J. Hamel4, Simon Kariuki3 and Jayne Webster2
Abstract 
Background: Coverage with malaria in pregnancy interventions remains unacceptably low. Implementation 
research is needed to identify and quantify the bottlenecks for the delivery and use of these life-saving interventions 
through antenatal clinics (ANC).
Methods: A cross-sectional study was carried out in ANC across nine health facilities in western Kenya. Data were 
collected for an individual ANC visit through structured observations and exit interviews with the same ANC clients. 
The cumulative and intermediate systems effectiveness for the delivery of intermittent preventive treatment (IPTp) 
and insecticide-treated nets (ITNs) to eligible pregnant women on this one specific visit to ANC were estimated.
Results: Overall the ANC systems effectiveness for delivering malaria in pregnancy interventions was suboptimal. 
Only 40 and 53 % of eligible women received IPTp by directly observed therapy as per policy in hospitals and health 
centres/dispensaries respectively. The overall systems effectiveness for the receipt of IPTp disregarding directly 
observed therapy was 62 and 72 % for hospitals and lower level health facilities, respectively. The overall systems 
effectiveness for ITNs for first ANC visit was 63 and 67 % for hospitals and lower level facilities, respectively.
Conclusion: This study found that delivery of IPTp and ITNs through ANC was ineffective and more so for higher-
level facilities. This illustrates missed opportunities and provider level bottlenecks to the scale up and use of interven-
tions to control malaria in pregnancy delivered through ANC. The high level of clustering within health facilities sug-
gest that future studies should assess the feasibility of implementing interventions to improve systems effectiveness 
tailored to the health facility level.
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Background
Each year 30 million pregnancies occur in areas of stable 
malaria transmission in sub-Saharan Africa [1]. Malaria 
in pregnancy can adversely affect the health of the 
mother and that of the unborn child and, if untreated, can 
lead to severe anaemia, maternal death, pregnancy loss or 
intrauterine growth restriction and/or preterm delivery 
leading to low birth weight [2]. In sub-Saharan Africa, 
it is estimated that about 40 % of all pregnancies would 
experience Plasmodium falciparum placental infection 
without malaria in pregnancy (MiP) preventive interven-
tions, which would result in an estimated 900,000 (Cred-
ibility Interval: 530,000–1,240,000) low birth weight 
deliveries every year [3]. However, MiP and its adverse 
effects are preventable. Through the use of the lives saved 
tool (LiST model) developed by the global Child Health 
Epidemiology Reference Group [4], it has been estimated 
that 94,000 neonatal deaths were prevented between 
2009 and 2012 through MiP interventions, and a further 
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200,000 could have been averted if coverage with MiP 
interventions were to have met the 2010 international 
target of 80 % [5].
WHO recommends effective case management, pre-
vention through insecticide-treated bed-nets (ITN) 
and intermittent preventive treatment (IPTp) with sul-
fadoxine–pyrimethamine for the control of malaria in 
pregnancy [6], which are proven to be efficacious and 
cost-effective interventions delivered through the ante-
natal care (ANC) platform. WHO recommendations, 
and Kenyan national guidelines state that IPTp should be 
administered at every ANC visit as early as possible dur-
ing the 2nd trimester. However, there is wide discrepancy 
between ANC coverage and MiP intervention coverage 
pointing to substantial missed opportunities. The Kenya 
Malaria Indicators Survey carried out in 2010, found that 
86 % of pregnant women in Kenya received antenatal care 
from a medical professional [7, 8]. However, coverage of 
at least one dose of IPTp with SP was 46 % and only 25 % 
of women received two or more doses (with at least one 
dose received through ANC). Although the proportion of 
women who receive two doses of IPT during pregnancy 
increased from 13 % in 2007–2009 to 21 % in 2010. Only 
half (49  %) of pregnant women reported that they slept 
under an ITN the previous night in 2008–09 [7]. A recent 
systematic review of 98 studies undertaken in sub-Saha-
ran Africa points to obstacles at all levels of implementa-
tion: from healthcare providers, health facility, as well as 
at higher levels of the health system [9]. Implementation 
research is needed to identify barriers to the scale-up 
of MiP interventions that can be used by local decision 
makers. The aim of this study was to measure the effec-
tiveness of ANC to deliver IPTp and ITNs, and to gain an 
understanding of where bottlenecks occur in the delivery 
process. The study does not intend to measure coverage 
of MiP interventions, which would require assessment of 
the whole pregnancy period (i.e. after birth) at the popu-
lation level.
Methods
Study site
The study was undertaken in the former Nyando Dis-
trict, Nyanza Province, in western Kenya between Feb-
ruary and May 2010. This area encompass the Nyando, 
Upper and Lower Nyakach, Miwani and Muhoroni 
Divisions and has been fully incorporated into Kisumu 
County. The former Nyando District had a population of 
355,800 (1999 census), with the majority of the popula-
tion from the Luo ethnic group. Malaria is perennial and 
holo-endemic with a parasite prevalence of 18 % among 
pregnant women presenting for their first ANC visit [10]. 
HIV prevalence among women in Nyanza Province is the 
highest across all provinces in the country (14  %, DHS 
2008–9 [7]). The former Nyando District has a total of 40 
health facilities of which 24 are owned by government, 
five by missions, seven privately owned and four are com-
munity run.
Study design and data collection
A cross-sectional study was conducted in nine out of ten 
selected health facilities using structured observation, 
exit interviews of an individual ANC visit with ANC cli-
ents and a health facility audit. This study was part of a 
larger programme under the Malaria in Pregnancy Con-
sortium using multi-disciplinary approaches to assess 
bottlenecks in the scale-up of malaria in pregnancy 
interventions. As part of this programme, healthcare 
provider’s perspective was examined through in-depth 
interviews following completion of observations in 2011, 
which will be presented separately, and the community 
perspective through both focus group discussions [11] 
and a household survey [12].
Sampling procedure
A list of all health facilities in the selected clusters for the 
associated household survey was compiled consisting of 
the health facilities that were closest to each cluster [12]. 
A dual-frame sampling scheme was used to purposively 
select the district hospital and a representative sample 
of nine health facilities using probability proportional to 
antenatal attendance. Note that community units (level 
1) were not included in the sampling frame as they did 
not provide antenatal care or deliver IPTp nor ITNs at 
the time of the study. All women attending ANC at the 
selected health facilities were invited to take part in the 
study and observations and exit interviews were carried 
out with all consented participants, except where there 
were 15 or more ANC attendees on the day at the time 
of registration, in which case exit interviews were con-
ducted only on every second woman who was observed 
which followed the registration order.
Data collection procedure
Data on characteristics of the health facility, demographic 
characteristics of the staff involved in delivery of ANC 
services, supplies and equipment necessary for ANC 
available on the day of the survey as well as stock records 
for the previous 1  year were collected from the health 
facility staff person in charge (or their representative on 
the day of the survey) using a structured questionnaire. 
A trained fieldworker was stationed at different points 
in the health facility to follow all the ANC processes: at 
registration desk, in the ANC consultation room, and at 
the exit to follow participants to the laboratory or phar-
macy and to conduct exit interviews. All ANC attend-
ees on each day of the survey were invited to take part 
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and, following provision of informed consent, participant 
characteristics were collected and all ANC processes 
observed and recorded using a structured checklist. The 
exit interviews were conducted immediately following 
the observations. The data collected through exit inter-
views included women’s knowledge of the treatments 
they received during ANC and on the dosing regimen of 
anti-malarials as well as measures of cost of prevention of 
malaria in pregnancy to their household.
Data analysis
Data were collected on paper forms and were double 
entered into EpiData (Version 3.1, EpiData Association, 
Odense, Denmark) and validated before being trans-
ferred to Stata (Version 13, 2013; College Station, TX) 
for analysis. Each intermediate step required for the 
effective delivery of IPTp and ITNs through ANC as per 
WHO guidelines [6] and Kenyan national policy [13] 
(Fig.  1) defined the framework for analysis (Fig.  2). The 
data collected were used to quantify: (1) the proportion 
of ANC attendees who successfully completed a desig-
nated intermediate step in the delivery of each interven-
tion from those who completed the previous step, (2) the 
cumulative systems effectiveness corresponding to the 
proportion of eligible ANC attendees who successfully 
completed all intermediate steps to the designated point 
in the overall delivery process, and (3) design effect (DE) 
and intra-cluster correlation coefficients (ICC) between 
health facilities for each intermediate step in the delivery 
of IPTp and ITNs. Predictors of ineffective intermediate 
steps will be described in a separate paper together with 
results from the qualitative data.
For the IPTp effectiveness analysis, IPTp eligibility was 
defined as per national policy at the time of the survey to 
include: reporting having felt the baby move (i.e. quicken-
ing) or estimated gestational age of 16 weeks or more (to 
ensure the mother was well past the first trimester, when 
SP is contraindicated); and not being HIV positive (as a 
proxy for no concurrent cotrimoxazole use). As informa-
tion on dates of previous ANC visits was not collected, it 
was not possible to assess if the last SP dose was within 
1 month, but this is unlikely to be a frequent occurrence.
For ITNs, the effectiveness analyses were restricted 
to participants presenting for their first ANC visit for 
the current pregnancy. Sample weights for observations 
were estimated based upon the sampling probability of 
each selected health facility [14]. Analyses were stratified 
for level 4 facilities (primary hospitals) and level 2 or 3 
(health centres and dispensaries) as a previous study in 
Mali showed that the systems effectiveness for the deliv-
ery of IPTp differed at different levels of the health sys-
tem [15]. As previously defined, intermediate steps were 
Fig. 1 Kenya guidelines for prevention of malaria in pregnancy (2008 edition) [13]
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classified as ‘ineffective’ if fewer than 80 % of participants 
successfully completed that step [16]. This is based on 
the fact that the Roll Back Malaria Partnership target for 
2015 was 100  % coverage for MiP interventions, which 
would mean that 100 % of women should pass each step 
of the delivery process for all to get the interventions. A 
realistic goal is that at least 80  % of women receive the 
interventions (the target for 2010) for which each step in 
the delivery should be at least 80 %.
Intermediate steps effectiveness
The effectiveness of each intermediate step in the deliv-
ery of MiP interventions was calculated by estimating the 
proportion of women who successfully completed each 
step [15, 16]. The intermediate steps for IPTp according to 
policy for eligible women (not on cotrimoxazole prophy-
laxis for the prevention of opportunistic infections asso-
ciated with HIV infection, and not administered another 
anti-malarial for treatment of malaria) were: (1): attend 
ANC consultation after quickening (estimated at around 
16 weeks gestation); (2): attend ANC when and where SP 
is in stock; (3): be given any SP; (4): be given three tab-
lets of SP; (5): be given SP by DOT or leaving the facility 
with three tablets of SP and able to report correctly how 
it should be taken. For ITNs the analysis was restricted to 
first ANC visits and there were four intermediate steps: 
(1) attend ANC for the first visit; (2) attend ANC when 
and where ITNs are in stock; (3) be offered an ITN and 
(4) take the ITN. Where ITN stock information was una-
vailable and no clients received ITNs from that facility on 
the day of the survey, these were classified as stock-outs 
for the effectiveness analysis.
The data were collected via structured observations 
except for ‘having three tablets of SP at exit with knowl-
edge of correct regimen’, which was obtained through 
exit interviews with ANC clients.
Cumulative systems effectiveness
The overall cumulative systems effectiveness was esti-
mated as the proportion of eligible pregnant women who 
successfully received each MiP intervention according to 
policy on the specific ANC visit. For IPTp two cumula-
tive systems effectiveness estimates were calculated (1) 
a ‘per policy’ estimate of being given three tablets of SP 
by directly observed therapy (DOT) and (2) being given 
three tablets of SP by DOT or without DOT, but women 
without DOT had three tablets of SP upon leaving the 
health facility and knew the correct dosing to take home 
(and, therefore, had the potential to receive a dose of 
IPTp-SP).
The design effect and intra‑cluster correlation coefficients
Design effect (DE) and intra-cluster correlation coef-
ficients (ICC) were used to measure the level of clus-
tering and correlation within health facilities. DE was 
calculated as the difference between the variance based 
Fig. 2 Intermediate steps in the delivery of IPTp-SP and ITN through antenatal care
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on the clusters used compared with a modelled variance 
if a simple random sample was used. DEs were calcu-
lated for each intermediate step (described above and in 
Fig.  2) aggregated for all health facilities combined and 
for health facilities clustered according to level 4 or level 
2 and 3 combined. ICC and DE are closely related and 
can be derived from one to the other using the following 
formula: DE = ICC × (m− 1)+ 1 where m is average 
number per cluster. This allows different ways of looking 
at clustering [17].
Ethics
The study was approved by the ethics committees of the 
Kenya Medical Research Institute (KEMRI), the U.S. 
Centers for Disease Control and Prevention (CDC), the 
London School of Hygiene and Tropical Medicine, and 
the Liverpool School of Tropical Medicine. Health work-
ers gave signed informed consent at the initial meeting 
for structured questionnaires and for structured obser-
vations. Pregnant women gave signed informed consent 
for observations and exit interviews immediately prior 
to beginning the ANC process. Permission from the Dis-
trict Health Management Teams was sought and heads 
of health facilities were informed before initiation of data 
collection.
Results
Data collection took place between first of March and 
28th of May 2010 in nine of the ten selected health facili-
ties. The Nursing Officer in charge of one health facility 
refused permission to collect data. A total of 792 preg-
nant women were enrolled and observations were carried 
out for 753 participants while exit interviews were con-
ducted with 613. For 39 participants enrolled, no obser-
vation was available as they did not receive antenatal care 
on the day of the survey and were therefore not included 
in the analysis: 23 women were sent home by the health 
facility staff due to lack of time either because they 
arrived late or because of long waiting time; six women 
came to the clinic but there were no ANC healthcare pro-
viders at the health facility on that day; four women were 
sent home as they came before their recommended ANC 
return visit date; two were sent to the labour ward; one 
was sent home as she didn’t have money to pay for the 
ANC laboratory tests and one was referred to another 
health facility with a laboratory to do the required ANC 
laboratory tests. Furthermore, two observations could 
not be carried out due to refusal from one healthcare 
provider and withdrawal from one participant after pro-
viding informed consent. Thirty-three participants com-
pleted part of the ANC process and were told to come 
back for the remaining processes on another day. These 
33 women were included in the analysis. One health 
facility, the mission hospital, was excluded from the sys-
tems effectiveness analysis as the IPTp policy was not 
implemented in this facility.
Description of health facility, healthcare providers 
and ANC attendees
All health facilities were government run with the excep-
tion of one health facility, which was a mission hospital 
but was then excluded from the analysis as described 
above (Table 1). There were four hospitals (level 4 facil-
ity), three health centres (level 3) and two dispensaries 
(level 2). The mean number of staff who usually provide 
ANC services was 5 (range 2–12). All facilities offered 
prevention of mother to child transmission of HIV 
(PMTCT) five days a week and the majority offered ANC 
5 days a week but two facilities had a specific day in the 
week for ANC and did not offer ANC services on other 
days. Three health facilities reported having support for 
ANC from a non-governmental organization (NGO) or 
research institute and seven had support for PMTCT 
from NGOs. Six of the nine facilities had a laboratory, 
five of which had a functioning microscope and all except 
one facility reported having drinking water available. All 
had at least two supervisory visits in the last 6 months, 
which included a visit to ANC for all but one facility. 
The majority of health facilities reported getting their 
drugs directly from the Kenya Medical Supplies Agency 
(KEMSA) and all but one facility had at least one episode 
of SP stock-out in the last 6 months. All health facilities 
reported that ITNs were Olyset® brand and were sup-
plied by Population Services International (PSI), and that 
ITNs were offered free of charge.
Overall 78 health workers were enrolled across nine 
health facilities (Table 2). The highest proportions (27 %) 
were registered nurse or midwifes, followed (14 %) medi-
cal or clinical officers; the rest included enrolled nurses, 
nurse students, laboratory technicians, pharmacists, 
nurse aids and community health workers based in the 
facilities. Over half (61.5  %) were female staff and the 
median age was 30 years (range 21–61). Of staff usually 
providing ANC care, 12.8  % had focused antenatal care 
training in last five years, 16.7  % had MiP training and 
52.6 % PMTCT specific training in the same period. The 
mean number of years they worked in the health facil-
ity was 2.3 (median 1 year, range 0–20). The majority of 
staff were of Luo ethnicity (72.0 %), 10.7 % were Kalenjin, 
9.3 % were Luyha and 6.7 % were Kisii.
The median age of the ANC attendees was 23  years 
(range 11–46) and 31  % were primigravid women 
(Table  3). For 43.7  % of women they participated on 
their first visit for the current pregnancy, for 23.4  % it 
was their 2nd visit, and 26.3 % presented for their 3rd or 
more visit. Median gestational age was 30 weeks (range 
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10–42) and only 1 % of women were in their first trimes-
ter. Nearly all women reported the reason for their visit 
to ANC was to receive routine care (95.8  %) and a few 
reported coming for both routine ANC and because of 
feeling unwell (2.8  %). The majority of ANC attendees 
were Luo (84.0 %) followed by Kalenjin (7 %) and Luyha 
(4.2 %).
Systems effectiveness of delivery of IPTp‑SP
Out of the 748 observations in the eight health facili-
ties, 546 participants were eligible for IPTp accord-
ing to national policy (Table  4). Of the 202 not eligible, 
117 (16 %) were HIV positive and assumed to be taking 
daily cotrimoxazole, 14 had a gestation <16  weeks and/
or hadn’t felt the baby move, and gestational age was 
unknown for 86 participants (note these are not mutually 
exclusive categories). Of the eligible women, only 45.8 % 
were given IPTp by DOT per policy. This was similar 
for level 4 (39.8 %) and levels 2 and 3 combined (53.3 %) 
(Fig. 3a). Two intermediate steps were identified as inef-
fective in the delivery of IPTp in level 4 facilities, namely: 
being given any SP (74.0  %) and being given IPTp by 
DOT (67.3 %). For health facilities level 2 and 3, the only 
ineffective step was being given IPTp by DOT (70.1 %) as 
80.3 % of eligible women were given SP during their ANC 
visit.
When either having SP at exit and having the knowl-
edge of how to take the three tablets at home or tak-
ing IPTp by DOT were considered as the final step in 
the delivery process, only the 576 participants with exit 
interviews were included. Of these, 428 were eligible for 
IPTp. The cumulative effectiveness was higher at 61.7 % 
for level 4 and 72.3 % for levels 2 and 3 combined respec-
tively (Fig. 3b) and the only ineffective step in the deliv-
ery process was being given any SP at level 4 facilities 
(Table 4).
Table 1 Description of the health facilities characteristics
Type 1 2 3 4 5 6 7 8 9
Sub‑district 
hospital
Sub‑district 
hospital
Dispensary District 
hospital
Mission 
hospital
Health 
centre
Dispensary Health 
centre
Health 
centre
Level 4 4 2 4 4 3 2 3 3
Catchment 
population
79,200 88,000 7500 23,400 6825 13,200 8100 5808 19,800
Number of 
ANC visits in 
2009
2734.00 1509.00 363.00 1156.00 500.00 449.00 807.00 1354.00 1038.00
Staffing
 Medical 
officer
1 1 1
 Clinical officer 9 2 1 6 1 1 2 1
 Pharmacist 1 1 1
 Public health/
registered 
nurse
8 8 3 12 6 6 2 3
 Enrolled nurse 10 6 6 2 1 2 2 4
 Assistant 
nurse
5
 Lab techni-
cian
3 3 2 4 2 2
Number of staff 
usually work-
ing in ANC
4 2 4 4 9 5 3 4 12
Time to closest 
referral centre 
(min)
45 60 45 30 30 90 60 60 30
Laboratory Yes Yes Yes Yes Yes Yes
Pharmacy Yes Yes Yes Yes Yes Yes Yes Yes
Number of 
observation
222 115 50 99 37 42 64 92 64
Number of exit 
interviews
128 115 50 57 37 35 56 86 49
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Systems effectiveness for delivery of ITNs
The overall cumulative effectiveness for the delivery of 
ITN during a first ANC visit was 65.3 % which is better 
than for the delivery of IPTp per policy (Table  5). Hos-
pitals (level 4 health facilities) performed similarly to 
dispensaries and health centres combined (levels 2 and 3 
respectively) where 63.1 and 67.4 % of first ANC attend-
ees respectively were offered and took an ITN (Fig.  4). 
The ineffective step in the ITN delivery process for level 
4 facilities was a woman being offered an ITN. Despite 
the cumulative effectiveness for level 2 and 3 facilities 
not reaching 80 %, all intermediate steps were considered 
effective (completed by >80 % of women). Stock-outs of 
ITNs was recorded in four of the eight health facilities 
included in this analysis restricted to first ANC visits, 
varying from 1 to 4 days of the survey.
Clustering and design effects for each intermediate 
delivery step
Table  6 shows the design effects and intra-cluster cor-
relation for each intermediate step in the delivery of 
IPTp and ITNs. Overall design effects and the cluster-
ing at health facility level were higher when looking at all 
health facilities and for levels 2 and 3 facilities combined 
compared to level 4 alone. For IPTp, two intermediate 
steps showed a high level of clustering: being given IPTp 
by DOT and having three tablets of SP when leaving the 
facility. This clustering and high design effect was appar-
ent across all groups (overall, level 4 and levels 2 and 3 
combined, respectively). For the delivery of ITNs, the 
design effect for the intermediate step of being offered 
an ITN was high for facility levels 2 and 3 combined but 
not for level 4. This is further illustrated in Additional 
file 1: Tables S1, S2, showing some facilities performing 
very well and others failing to deliver the interventions 
adequately. In particular, one dispensary delivered IPTp 
by DOT to 94 % of eligible clients and 100 % of clients 
coming for their first visit received an ITN. At the other 
end of the spectrum, there were a high number of missed 
opportunities in one health centre with close to 70  % 
of eligible clients leaving the facility without receiving 
any SP for IPTp (despite SP being in stock), no women 
Table 2 Characteristics of  health workers enrolled in  health facilities where  ANC observations took place (number (%) 
unless otherwise specified)
 FANC focused antenatal care, MiP malaria in pregnancy, PMTCT prevention of mother to child transmission of HIV, SD standard deviation
Health facility 1 2 3 4 5 6 7 8 9 Overall
Number of staff interviewed 16 8 3 16 7 5 2 9 12 78
Number female 9 (56.3) 3 (37.5) 3 (100.0) 11 (68.8) 4 (57.1) 4 (80.0) 2 (100.0) 3 (33.3) 9 (75.0) 48 (61.5)
Mean age in years (SD) 29 (8) 34 (8) 34 (8) 31 (7) 34 (11) 34 (11) 38 (5) 37 (11) 34 (10) 33 (9)
Number resident in the district 3 (18.8) 0 (0.0) 1 (33.3) 4 (25.0) 1 (14.3) 1 (20.0) 0 (0.0) 6 (66.7) 3 (25.0) 21 (25.6)
Number from district 4 (25.0) 1 (12.5) 1 (33.3) 1 (43.8) 3 (42.9) 1 (20.0) 1 (50.0) 6 (66.7) 4 (33.3) 31 (37.8)
Ethnicity 
 Luo 6 (46.2) 5 (62.5) 3 (100.0) 14 (93.3) 6 (85.7) 2 (40.0) 2 (100.0) 8 (88.9) 7 (58.3) 53 (71.6)
 Luyha 4 (30.8) 0 0 0 0 0 0 1 (11.1) 2 (16.7) 7 (9.5)
 Kalenjin 1 (7.7) 2 (25.0) 0 1 (6.7) 0 1 (20.0) 0 0 3 (25.0) 8 (10.8)
 Kisi 2 (15.4) 1 (12.5) 0 0 1 (14.3) 1 (20.0) 0 0 0 5 (6.8)
 Other 0 0 0 0 0 1 (20.0) 0 0 0 1 (1.4)
Mean years in health facility (SD) 0 (1) 2 (3) 3 (5) 2 (2) 3 (3) 0 (0) 4 (2) 7 (7) 3 (3) 2 (4)
Number working in other departments 15 (93.8) 7 (87.5) 2 (66.7) 12 (80.0) 6 (85.7) 4 (80.0) 2 (100.0) 9 (100.0) 11 (91.7) 72 (88.9)
Highest qualifications 
 Medical or clinical officers 3 2 0 3 1 1 0 0 1 11
 Pharmacist 1 0 0 1 0 0 0 0 0 2
 Registered nurse/midwife 2 2 2 4 4 3 0 0 4 21
 Enrolled nurse/midwife 1 0 1 0 0 1 0 0 3 6
 Nurse aid 0 0 0 0 1 0 0 0 0 1
 Laboratory technician 1 1 0 2 1 0 0 2 1 8
 Student 6 0 0 0 0 0 0 0 2 8
 Other 1 1 1 1 0 0 0 5 0 9
Number with FANC training in last 5 years 4 (25.0) 1 (12.5) 1 (33.3) 1 (6.25) 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1) 2 (16.7) 10 (12.2)
Number with PMTCT training in last 5 years 6 (37.5) 4 (50.0) 2 (66.7) 10 (62.5) 3 (42.9) 2 (40.0) 1 (50.0) 7 (77.8) 6 (50.0) 41 (50.0)
Number with MiP in training last 5 years 3 (8.8) 3 (37.5) 1 (33.3) 2 (12.5) 1 (14.3) 0 (0.0) 0 (0.0) 2 (2.2) 1 (9.3) 15 (15.9)
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receiving IPTp by DOT and 65  % of first visits leaving 
ANC without an ITN.
Discussion
This study found that the systems effectiveness of ANC 
to deliver IPTp was unacceptably low and only slightly 
better for ITNs. The majority of health facilities failed 
to deliver these interventions to 80 % of eligible women. 
The findings illustrate clear missed opportunities for pro-
tecting women and their unborn babies from the adverse 
effects of MiP and the need to maximize the public health 
impact of these cost-effective interventions.
Despite presenting to ANC and being eligible for IPTp, 
over 54 % of pregnant women did not receive a dose of 
IPTp by DOT and 33 % did not receive any SP (either by 
DOT or to take home) despite SP being in stock. The sys-
tem effectiveness was slightly better for health centres 
and dispensaries compared to hospitals with 80 % of eli-
gible women receiving some SP for IPTp, although only 
53 % received the correct dose by DOT overall, compared 
to 62 and 40 % in hospitals for any IPTp and IPTp by DOT, 
respectively. Although stock-out of SP has been reported 
as a major issue in previous studies, in this study no 
stock-outs were observed on the days of visit despite the 
fact that facilities reported SP stock-outs in the preced-
ing 12 months [9]. These cumulative system effectiveness 
estimates cannot be compared to overall IPTp coverage 
(i.e. 25 % for Kenya in 2010 [8] or 17 % for Nyanza Prov-
ince [7]) as the presented estimates are derived from a 
cross-section of pregnant women not capturing the IPTp 
coverage for the whole pregnancy period and represent 
IPTp eligible women coming to ANC whereas estimates 
from demographic health surveys and/or malaria indi-
cator surveys are based on household surveys involving 
women who gave birth in the previous years disregard-
ing if they have been to ANC or if they had a contraindi-
cation, such as taking cotrimoxazole and fail to capture 
pregnancy not ending in a live births (estimate close to 
30 % of pregnancies for Kenya [1]). The system effective-
ness for delivery of ITNs was better than for IPTp, but 
Table 3 Characteristics of  pregnant women (number (%) 
unless otherwise specified)
Level 4 Level 3 Level 2 Overall
Number 473 198 114 785
Mean age (SD) 23.8 (5.9) 23.5 (5.6) 24.7 (6.8) 23.9 (6.0)
Age group
 <15 years 4 (0.9) 3 (1.5) 2 (1.8) 9 (1.2)
 15–20 years 117 (24.7) 48 (24.2) 28 (24.6) 193 (24.6)
 20–29 years 269 (56.9) 114 (57.6) 57 (50.0) 440 (56.1)
 30–39 years 75 (15.9) 30 (15.2) 22 (19.3) 127 (16.2)
 40–49 years 8 (1.69) 1 (0.5) 4 (3.5) 13 (1.7)
 ≥50 years 0 (0.0) 2 (1.0) 1 (0.9) 3 (0.4)
Marital status
 Single 77 (16.5) 40 (20.2) 17 (15.0) 134 (17.3)
 Married 384 (82.4) 154 (77.8) 92 (81.4) 630 (81.2)
 Divorced 2 (0.4) 3 (1.5) 4 (3.5) 9 (1.2)
 Widowed 3 (0.6) 1 (0.5) 0 (0.0) 4 (0.5)
Highest level of education
 None 144 (30.4) 84 (42.4) 70 (61.4) 298 (38.0)
 Primary 271 (57.3) 99 (50.0) 38 (33.3) 408 (52.0)
 Secondary 41 (8.7) 11 (5.6) 5 (4.4) 57 (7.3)
 Higher education 17 (3.6) 4 (2.0) 1 (0.9) 22 (2.8)
Gravidity 
 Primi 145 (30.7) 71 (35.9) 27 (23.7) 243 (31.0)
 2–3 272 (57.5) 101 (51.0) 56 (49.1) 429 (54.7)
 4+ 56 (11.8) 26 (13.1) 31 (27.2) 113 (14.4)
Number of children under 5
 0 209 (44.6) 85 (43.2) 35 (31.5) 329 (42.3)
 1 141 (30.1) 65 (33.0) 37 (33.3) 243 (31.3)
 2–4 117 (25.0) 45 (22.8) 39 (35.1) 201 (25.9)
 5+ 2 (0.4) 2 (1.0) 0 (0.0) 4 (0.5)
Socioeconomic status group 
 Poorest 44 (13.1) 28 (16.5) 51 (48.1) 123 (20.1)
 Very poor 54 (16.0) 50 (29.4) 19 (17.9) 123 (20.1)
 Poor 63 (18.7) 45 (26.5) 14 (13.2) 122 (19.9)
 Less poor 79 (23.4) 29 (17.1) 15 (14.2) 123 (20.1)
 Least poor 97 (28.8) 18 (10.6) 7 (6.6) 122 (19.9)
 Missinga 136 28 8 172
Gestation trimester 
 First 12 (2.5) 5 (2.5) 3 (2.6) 20 (2.6)
 2nd 155 (32.8) 68 (34.3) 36 (31.6) 259 (33.0)
 3rd 228 (48.2) 98 (49.5) 67 (58.8) 393 (50.1)
 Missing 78 (16.5) 27 (13.6) 8 (7.0) 113 (14.4)
ANC visit number 
 1 190 (40.2) 111 (55.8) 43 (37.4) 344 (43.7)
 2 117 (24.7) 35 (17.6) 32 (27.8) 184 (23.4)
 3 82 (17.3) 22 (11.1) 19 (16.5) 123 (15.6)
 4 32 (6.8) 8 (4.0) 12 (10.4) 52 (6.6)
 5 6 (1.3) 2 (1.0) 0 (0.0) 8 (1.0)
 6 3 (0.6) 2 (1.0) 0 (0.0) 5 (0.6)
 Missing 43 (9.1) 19 (9.6) 9 (7.8) 71 (9.0)
Table 3 continued
Level 4 Level 3 Level 2 Overall
Reason for visit
 Routine ANC 325 (95.9) 162 (95.3) 102 (96.2) 587 (95.8)
 Routine ANC + ill 2 (0.6) 3 (1.8) 1 (0.9) 6 (1.0)
 Ill 10 (3.0) 4 (2.4) 3 (2.8) 17 (2.8)
 Missing 136 29 8 175
a Information on assets was only collected for participants completing exit 
interviews
 ANC antenatal care; SD standard deviation
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Table 4 Intermediate and  cumulative system effectiveness for  the delivery of  IPTp with  and without  directly observed 
therapy (DOT) through the antenatal care platform
a IPTp eligibility according to Kenya national guidelines was women not taking cotrimoxazole (or being HIV positive as a proxy for cotrimoxazole use), having felt the 
baby move (i.e. past quickening) or being 16 weeks gestation or over
b Analysis limited to participants completing exit interviews where information on availability of SP at exit was collected
ANC antenatal care; CI confidence interval, DOT directly observed therapy, IPTp intermittent preventive treatment SP sulfadoxine–pyrimethamine
Level 4 Levels 3 and 2
n Intermediate Cumulative n Intermediate Cumulative
% (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI)
With DOT
 IPTp eligiblea 304 242
 SP in stock 304 100.0 100.0 242 100.0 100.0
 Receive SP during visit 208 68.6 [60.2, 75.9] 68.6 [60.2, 75.9] 198 80.3 [61.7, 91.1] 80.3 [61.7, 91.1]
 Receive three doses SP during visit 206 99.0 [96.1, 99.7] 67.8 [60.6, 74.3] 187 94.1 [77.5, 98.7] 75.5 [55.4, 88.5]
 Took SP by DOT 121 64.6 [22.2, 92.1] 39.8 [12.5, 75.4] 129 70.1 [22.1, 95.1] 53.3 [21.0, 83.1]
With or without DOTb
 IPTp eligiblea 208 220
 SP in stock 208 100.0 100.0 220 100.0 100.0
 Being given SP during visit 140 67.5 [60.3, 74.0] 67.5 [60.3, 74.0] 181 79.7 [60.8, 90.9] 79.7 [60.8, 90.9]
 Being given three doses SP during visit 139 99.2 [96.2, 99.9] 67.0 [60.6, 72.8] 170 93.4 [74.5, 98.6] 74.5 [53.6, 88.1]
 Has SP on exit 52 88.0 [63.3, 96.9] 40.3 [18.2, 67.2] 50 93.4 [45.9, 99.6] 54.0 [17.6, 86.5]
 Knows to take three tablets SP 48 92.1 [78.1, 97.5] 37.2 [17.7, 61.9] 49 96.4 [59.6, 99.8] 52.5 [16.3, 86.2]
 SP by DOT 80 58.3 [19.3, 89.1] 39.1 [15.9, 68.6] 118 71.0 [22.9, 95.3] 52.9 [20.2, 83.2]
 Knows to take three tablets SP or took SP as DOT 128 92.1 [87.4, 95.1] 61.7 [55.7, 67.4] 167 97.1 [70.6, 99.8] 72.3 [46.9, 88.6]
Fig. 3 a Cumulative system effectiveness for the delivery of IPTp-SP by DOT through ANC and b Cumulative system effectiveness for the delivery 
of IPTp-SP through ANC either by DOT or pregnant women having three tablets of SP at exit and knowing how to take them. Intermediate steps are 
as follows: step 1, Eligible pregnant women attend ANC in her second trimester; step 2, SP is in stock; step 3, SP is given to the pregnant women; step 
4, the correct dose of SP is given (three tablets); step 5, the pregnant women take IPTp-SP by DOT (a) or either by DOT or pregnant women having 
three tablets of SP at exit and knowing how to take them (b)
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still underlines missed opportunities with close to 35  % 
of first ANC attendees leaving a health facility without 
an ITN. Even though all the intermediate steps for the 
delivery of ITNs (namely presenting for a first ANC visit; 
ITNs being in stock at ANC on the day; being offered an 
ITN and taking the ITN), were effective for health cen-
tres and dispensaries, only 67 % of women coming for a 
first ANC visit left these facilities with an ITN. In hos-
pitals, only 70  % of women were offered an ITN when 
they were in stock and the cumulative effectiveness was 
63  %. Furthermore, missed opportunities were high-
lighted by 37 women (5  %) who presented to the clinic 
but didn’t receive ANC services for a variety of reasons 
ranging from late arrival at ANC, absent ANC health-
care providers, presenting before the recommended 
ANC return visit date, and need for ANC laboratory tests 
that were not available at the facility. Thirty-three (4 %) 
women didn’t complete their ANC visit, mainly due to 
delays at the laboratory, and were asked to come back the 
next working day. Of these only 3  % received IPTp and 
12 % received an ITN. It is unknown what proportion of 
women returned to complete their visit as scheduled by 
the healthcare provider, but given the known barriers for 
attending ANC (such as commitment to farming, child-
care, employment and transport cost) this is likely to be a 
small proportion [9].
A household cross-sectional study conducted concur-
rently alongside the health facility survey [12] found low 
IPTp coverage, with 59  % of recently pregnant women 
who attended ANC at least once between 4 and 9 months 
gestation reporting to have received one dose of SP. The 
household survey showed that among women who vis-
ited ANC at least twice during pregnancy 27 % received 
two doses of IPTp and only 14  % by DOT. Due to the 
Table 5 Intermediate and cumulative system effectiveness for the delivery of ITN at first antenatal care visit
 ANC antenatal care, CI confidence interval, ITN, insecticide-treated net
Steps for ITN delivery Level 4 Levels 3 and 2
n Intermediate Cumulative n Intermediate Cumulative
% (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI)
Attend ANC 142 100.0 135 100.0
ITN in stock 127 90.0 [76.9, 96.1] 90.0 [76.9, 96.1] 115 82.6 [47.6, 96.1] 82.6 [47.6, 96.1]
Given ITN during consultation by healthcare provider 91 70.1 [54.3, 82.2] 63.1 [55.9, 69.7] 94 83.0 [61.2, 93.8] 68.6 [38.0, 88.6]
Women took ITN 91 100 63.1 [55.9, 69.7] 93 98.4 [81.8, 99.9] 67.4 [35.6, 88.6]
Fig. 4 Cumulative system effectiveness for the delivery of ITN through ANC stratified for health facility level 4 and 2/3 combined. Intermediate 
steps are as follows: step 1 attend ANC for first visit; step 2 ITN are in stock; step 3 an ITN is offered to the women; step 4 the women accepts and takes 
the ITN
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cross-sectional nature of the health facility survey, the 
authors were unable to assess the proportion of preg-
nant women receiving at least two doses of IPTp during 
pregnancy, which requires data for the whole pregnancy 
period. Findings from the household survey suggest that 
the major bottlenecks occur at the health facility level, as 
reflected by the discrepancy between the proportions of 
women who attended ANC at least twice in an eligible 
gestation (78 %) and those receiving at least two doses of 
IPTp (27 %). Three quarter of participants who received 
either dose of IPTp said they received it by DOT, which is 
higher than the proportion observed in the health facility 
survey (58 % for hospitals and 65 % for health centres and 
dispensaries combined).
A related study evaluating the health systems effective-
ness of ANC to deliver MiP interventions in Mali [15, 18] 
found that delivery of IPTp through ANC was ineffec-
tive, with 0 and 25 % of eligible women receiving IPTp by 
DOT at the district and community levels, respectively. 
The cumulative systems effectiveness of being given IPTp 
with or without DOT was also better in Mali, at 56 and 
67  % for the district and community levels respectively. 
Despite the different study/country contexts, such as the 
higher HIV prevalence in Kenya and differing national 
guidelines on IPTp, similar cumulative effectiveness were 
observed in Kenya, with 62 % for hospitals and 72 % for 
health centres and dispensaries. As with the Kenya find-
ings, the ineffective steps in Mali were being given any SP 
and receiving IPTp by DOT, with higher-level facilities 
having the least effective delivery.
Similar to the Mali study, there was a significant clus-
tering of effective and ineffective steps and outcomes 
by health facility as reflected by the high design effects. 
Steps such as receiving IPTp by DOT or being given SP 
to take home varied across facilities with some facili-
ties always and others never giving IPTp by DOT. This 
Table 6 Design effect and intra-cluster correlation for each intermediate step for the delivery of ITN and IPTp
a IPTp eligibility according to Kenya national guidelines was women not taking cotrimoxazole (or being HIV positive as a proxy for cotrimoxazole use), having felt the 
baby move (i.e. past quickening) or being 16 weeks gestation or over
ANC antenatal care, DE design effect, DOT directly observed therapy, ICC intra-class correlation, IPTp intermittent preventive treatment, ITN insecticide-treated net, SP 
sulfadoxine–pyrimethamine
Delivery 
steps
Level 4 Level 3 and 2 Overall
% Pregnant 
women
% Range DE ICC % Pregnant 
women
% Range DE ICC % Pregnant 
women
% Range DE ICC
ITN eligible: 
attend ANC 
first visit
100.0 100 100
 ITN in stock 90.9 (84.9–100.0) 3.1 0.023 100 94.8 (84.9–100.0) 5.1 0.044
 Offered an 
ITN
63.4 (55.6–74.2) 0.7 −0.003 68.6 (35.3–100.0) 9.1 0.087 66.0 (35.3–100.0) 4.4 0.037
IPTp eligiblea 100.0 100 100
 SP in stock 100.0 100 100
 Seen at ANC 
consulta-
tion
100.0 100.0 99.7 (98.6–100.0) 0.7 −0.003 99.9 (98.5–100.0) 0.9 -0.001
 Being given 
SP during 
visit
68.6 (61.5–73.2) 2.2 0.013 80.3 (60.7–95.7) 6.8 0.062 74.0 (60.7–95.7) 4.6 0.039
 Being given 
three tabs 
SP during 
visit
99.0 (98.2–100.0) 0.9 −0.001 94.1 (76.5–100.0) 5.1 0.044 96.5 (46.4–95.7) 4.9 0.042
 SP by DOT 64.6 (0.0–86.9) 38.0 0.398 70.1 (24.1–100.0) 34.2 0.357 67.3 (24.1–100.0) 29.0 0.301
 Has SP on 
exit
36.7 (11.3–96.6) 26.0 0.269 27.1 (0–80.0) 28.7 0.298 31.5 (0–96.6) 22.3 0.229
 Knows to 
take three 
tablets SP
92.1 (85.7–100.0) 1.0 0.000 96.4 (87.5–100.0 2.7 0.018 94.2 (85.7–100.0) 1.7 0.008
 Knows to 
take three 
tablets SP 
or took SP 
as DOT
92.1 (86.2–93.8) 0.6 −0.004 97.1 (70.0–100.0) 6.4 0.058 94.8 (70.0–100.0) 2.9 0.020
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clustering calls attention to the need for targeted inter-
ventions to improve the delivery of MiP interventions 
at the health facility level. These could be implemented 
through enhanced supervisory visits to selected facilities.
This study provides insights on the health facility 
level barriers to effective delivery of MiP interventions, 
however, several limitations should be noted. First, the 
approach used in the study presented here differed from 
the health facility survey carried out in Mali in that sur-
vey staff were placed at different stations in ANC to cap-
ture all consenting women on the day of the survey. In 
Mali, each enrolled participant was followed by one study 
staff from the beginning of the ANC process until they 
exited the clinic. Although in Kenya all women could be 
observed on the day, in busy health facilities not all par-
ticipants could be interviewed at exit as the turnover 
was usually faster than the time it took to complete the 
interview.
Secondly, the authors were not able to exclude women 
who received SP within the last 4  weeks which could 
under-estimate the cumulative systems effectiveness 
by including IPTp ineligible participants in the analysis. 
Assuming about a third of pregnant women make the 
minimum recommended number of four visits (34  % 
according to the concurrent household survey [12]), this 
could have been the case for some of the revisits. Also 
participants with unknown gestational age (4  %) could 
not be included in the IPTp effectiveness analysis as their 
eligibility could not be established. However, including 
these participants assuming that they were beyond the 
first trimester (median gestation at first ANC visit was 
5 months in household survey, well into the second tri-
mester [12]) only slightly affect the cumulative effective-
ness of receiving IPTp by DOT (it was 42 % for hospitals 
and 52  % for lower level facilities compared to 40 and 
55  % overall, respectively, and the cumulative effective-
ness for with or without DOT were 55 and 74  % com-
pared to 62 and 72 %, respectively).
ITN stock information was not available for nine sur-
vey days from two health facilities for which stock-out 
was assumed, however if ITNs were in stock on those 
days the cumulative effectiveness would not have been 
affected but the intermediate step of being offered an ITN 
in health centres and dispensaries becomes ineffective at 
69 %. There could have been errors in data collection as 
data from observations may reflect the Hawthorne effect 
[19], data from exit interviews from social desirability 
bias [20], and data extracted from ANC registers may 
have been incomplete or erroneously abstracted. How-
ever, given the low observed cumulative effectiveness for 
each of the endpoints it seems unlikely that these factors 
would have an impact on the outcomes and, if anything, 
would over-estimate ANC delivery effectiveness. Lastly, 
the selected mission hospitals could not be included as 
one facility did not implement the policy for IPTp, and 
ITNs and SP for IPTp were out of stock for the whole 
study period and the other mission hospital refused to 
take part in the study. There is limited information on 
quality of care or system effectiveness of ANC for deliv-
ery of MiP interventions in these settings. It will be 
important for future studies to be inclusive of the mission 
run health facilities and private sector, given that care in 
that sector is growing and it provides health services to a 
significant proportion of the population in sub-Saharan 
Africa [21].
Conclusion
This study identified that the delivery of MiP interven-
tions through the ANC platform in this setting—namely 
the delivery of IPTp and ITNs in hospitals, and of IPTp by 
DOT at all health facility levels—was ineffective. The sub-
stantial variation observed between health facilities sug-
gests that future intervention studies to increase uptake 
of IPTp and ITNs, as well as other ANC services, should 
focus on identifying facility level problems and evaluating 
customized solutions. Special attention should be given 
to the private sector, for which very little information on 
ANC and quality of care in general is available. Overall, 
the ANC systems effectiveness for delivering MiP inter-
ventions was suboptimal and highlights missed opportu-
nities to protect pregnant women and their babies from 
the adverse consequences of malaria. These are cost-
effective interventions with the potential of saving many 
lives. Qualitative data collected alongside the quantitative 
data in this survey will provide further insights on the 
reasons for these missed opportunities and potential tai-
lored interventions.
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